the Oxford-GSK Institute of Molecular and Computational Medicine
The genetic and genomic revolution of the past decade has amassed vast datasets of promising targets for medicine discovery. These datasets can be combined with functional genomics to provide deep understanding of disease at a molecular level. By harnessing this understanding, as well as the power of machine learning, the Institute aims to uncover new indicators and predictors of disease and use them to accelerate the most promising areas for drug discovery.
This site introduces the innovative approach, research areas, ambitions and the team making it all happen. Formed in 2022, and fully recruited by Q3 2023, the institute is already making significant progress in its work.
Welcome from the Directors of the Oxford-GSK Institute of Molecular and Computational Medicine.
In this video they discuss the opportunities that cutting edge tech can offer in helping patients with neurodegenerative diseases.
Professor John Todd (Oxford) (pictured left) and Dr Tony Wood (GSK) (pictured right) are joint directors of the Oxford-GSK Institute of Molecular and Computational Medicine.
News
-
Our First Oxford-GSK Fellow
5 December 2023
-
Our Team
31 August 2023
-
Progress in 2023 - putting data to work for patients
31 August 2023
TEAM FOCUS
"What brought me here is the opportunity to delve into multi-omics data analysis, contribute to the development of a collaborative cloud analytics platform, and gain a better understanding of neurodegenerative diseases at a molecular level. I am particularly excited by the prospect of collaborating with brilliant researchers from diverse scientific backgrounds."
Anand Maurya, Bioinformatician